ABL Bio Inc. (KOSDAQ:298380)
South Korea · Delayed Price · Currency is KRW 89,100
-4,500 (-4.81%)
Aug 11, 2026, 3:30 PM KST
ABL Bio Revenue
ABL Bio had revenue of 13.14B KRW in the quarter ending March 31, 2026, with 506.83% growth. This brings the company's revenue in the last twelve months to 90.32B, up 226.89% year-over-year. In the year 2025, ABL Bio had annual revenue of 79.35B with 137.55% growth.
Revenue (ttm)
90.32B
Revenue Growth
+226.89%
P/S Ratio
58.02
Revenue / Employee
885.50M
Employees
102
Market Cap
5.24T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.35B | 45.95B | 137.55% |
| Dec 31, 2024 | 33.40B | -32.14B | -49.04% |
| Dec 31, 2023 | 65.55B | -1.75B | -2.61% |
| Dec 31, 2022 | 67.30B | 61.97B | 1,162.19% |
| Dec 31, 2021 | 5.33B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Epis Holdings | 1.51T |
| SK Biopharmaceuticals | 790.25B |
| SK bioscience | 665.42B |
| Hugel | 479.57B |
| LigaChem Biosciences | 125.87B |
| HLB Co., Ltd. | 85.20B |
| OliX Pharmaceuticals | 17.26B |
| Voronoi | 7.51B |